Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option
Nippon Life India Asset Management Limited · Direct Plan · Growth
Fund overview
1% on or before 1M, Nil after 1M
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹5,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹5,000 | ₹5,840 | +840 |
| 3 Years | ₹5,000 | ₹7,968 | +2,968 |
| 5 Years | ₹5,000 | ₹10,870 | +5,870 |
Calculated using the fund's annualised return since inception (16.8% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
36 securitiesTop 10 holdings make up 53.2% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 11.71% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 7.10% |
| Lupin Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 6.17% |
| Cipla Ltd | Pharmaceuticals & Biotechnology | Large Cap | 6.01% |
| Dr. Reddys Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 5.45% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 4.89% |
| Mankind Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.38% |
| SAI Life Sciences Ltd | Pharmaceuticals & Biotechnology | Small Cap | 3.92% |
| Ajanta Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.61% |
| Glaxosmithkline Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.11% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹9,166 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹8,919 Cr
Exit load, stamp duty & tax
01-Jan-13
1% on or before 1M, Nil after 1M
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | 14.96% |
| Beta | 0.93 |
| Sharpe Ratio | 3.04 |
| Sortino Ratio | 0.18 |
| Treynor Ratio | 0.49 |
| Jensen's Alpha | 4.07 |
| Information Ratio | 0.17 |
| R-Squared | 98.44% |
| Max Drawdown | -3.27% |
| Upside Capture | 98.76% |
| Downside Capture | 77.75% |
Fund management
Scheme Details
Investment objective
The Primary Investment Objective Of The Scheme Is To Generate Consistent Returns By Investing In Equity / Equity Related Or Fixed Income Securities Of Pharma And Other Associated Companies
Fund house
Nippon Life India Asset Management Limited
Frequently asked questions
What is the NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is ₹595.37 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The expense ratio charged by Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 1%.
What is the Min. SIP of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The minimum SIP investment in Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is ₹100 per month.
What is the Min. Lumpsum of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The minimum lumpsum investment in Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is ₹5,000.
What is the Exit Load of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The exit load for Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is: 1% on or before 1M, Nil after 1M
.svg){kind=small}